Connect with us

Health

ESMO Guidelines Discourage Delayed, Discontinued Treatment During the COVID-19 Pandemic – OncLive

Any type of anti-cancer therapy that could impact overall survival should not be discontinued or delayed.

Published

on

post featured image

Any type of anti-cancer therapy that could impact overall survival (OS) should not be discontinued or delayed, according to a European Society for Medical Oncology (ESMO) interdisciplinary expert consensus paper on how to manage patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic.1
The guidelines, which were recently published in the Annals of Oncology,2 also discourage classifying all patients with cancer as especially vulnerable to COVID-19, regardless of age, gender,…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending